Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD/CBD-A for Neuropathic Pain in Spinal Cord Injury
NCT05630235Phase 2Completed
- Sponsor
- University of Miami
- Start
- Jun 2025
- Primary completion
- Aug 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cannabidiol and cannabidiolic acid in neuropathic pain (2 arms), sponsored by University of Miami. Primary endpoints: Change in neuropathic pain intensity or unpleasantness at 6 hours and Change in brain electrocortical activity at rest at 3 hours. Started Jun 2025; status: completed.
02
Drugs
cannabidiolcannabidiolic acid
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT05630235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630235.